$12 does not do what we have lined up any justice. I am legitimately waiting for $20+, in which I am very confident we will get. If we are going to already start knocking on $6 as shown by that chart, once FDA approves trof, NEU will then apply for other indications including Autism. Our other pipeline drugs currently in development with one of them looking even more promising than trofinitide, we have a very bright future to look forward to.
NEU chart, page-52
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$16.57 |
Change
2.170(15.1%) |
Mkt cap ! $2.117B |
Open | High | Low | Value | Volume |
$14.85 | $16.67 | $14.60 | $24.77M | 1.544M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | $16.52 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$16.57 | 1717 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1500 | 16.520 |
2 | 400 | 16.480 |
1 | 300 | 16.470 |
2 | 1367 | 16.440 |
2 | 5242 | 16.400 |
Price($) | Vol. | No. |
---|---|---|
16.570 | 1717 | 1 |
16.590 | 1367 | 2 |
16.600 | 4715 | 3 |
16.620 | 2306 | 2 |
16.650 | 2000 | 1 |
Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
EQN
EQUINOX RESOURCES LIMITED.
Zac Komur, MD & CEO
Zac Komur
MD & CEO
SPONSORED BY The Market Online